BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38056161)

  • 1. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
    Feng R; Cheng D; Chen X; Yang L; Wu H
    Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
    Xu X; Wang J
    Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
    Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
    Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constructing and validating of m7G-related genes prognostic signature for hepatocellular carcinoma and immune infiltration: potential biomarkers for predicting the overall survival.
    Liu P; Dong C; Shi H; Yan Z; Zhang J; Liu J
    J Gastrointest Oncol; 2022 Dec; 13(6):3169-3182. PubMed ID: 36636051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
    Yu Y; Lou Y; Zhu J; Wang X
    Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
    Wang L; Wang Q; Li Y; Qi X; Fan X
    J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
    Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis and Validation of Tyrosine Metabolism-related Prognostic Features for Liver Hepatocellular Carcinoma Therapy.
    Cui Z; Liu C; Li H; Wang J; Li G
    Curr Med Chem; 2024 Feb; ():. PubMed ID: 38415454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
    Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
    Front Genet; 2021; 12():785185. PubMed ID: 34917132
    [No Abstract]   [Full Text] [Related]  

  • 14. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic analysis of
    Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
    Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
    Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
    PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
    Yang Y; Zhao W; Du J; Wang Y
    Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis.
    He Q; Fan B; Du P; Jin Y
    Front Cell Dev Biol; 2022; 10():806989. PubMed ID: 35356272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.